Anxiolytic activity of pyridoindole derivatives SMe1EC2 and SMe1M2: behavioral analysis using rat model
Open Access
|Feb 2012References
- Atack JR. (2003). Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site.(4): 213-232.
- Balonová T, Zeljenková D, Ďurišová M, Nosáľ R, Jakubovský J, Líška J, Štolc S. (1991). Reproductive toxicity studies with cis- (-)-2,3,4,4a,5,9b-hexahydro-2,8-dimethyl-1-pyrido[4,3-b]indole dipalmitate in rats.(1): 5.
- Barkov NK. (1973). On the Mode of Carbidine Action.(4): 154-157.
- Barnard EA, Skolnick P, Olsen RW, Mohler H, Sieghart W, Biggio G, Braestrup C, Bateson AN, Langer SZ. (1998). International Union of Pharmacology. XV. Subtypes of gamma-aminobutyric acidA receptors: classification on the basis of subunit structure and receptor function.(2): 291-313.
- Basile AS, Lippa AS, Skolnick P. (2004). Anxioselective anxiolytics: can less be more?(1-3): 441-51.
- Braestrup C and Squires RF. (1977). Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding.(9): 3805-3809.
- Chalupa I, Blasko M, Benes L. (1993). In vitro micronucleus test of the cardioprotective agent stobadine. A genotoxicological study.: 206-207.
- Crestani F, Martin JR, Möhler H, Rudolph U. (2000). Mechanism of action of the hypnotic zolpidem in vivo.(7): 1251-1254.
- Dubovický M, Ujházy E, Kovacovský P, Rychlík I, Jansák J. (1999). Evaluation of long-term administration of the antioxidant stobadine on exploratory behavior in rats of both genders.(6): 431-436.
- Dubovický M, Ujházy E, Kovačovský P, Rychlík I, Kalnovičová T, Navarová J, Turčáni P, Durišová M, Gajdošík A. (1997a). Effect of long-term administration of stobadine on exploratory behaviour and on striatal levels of dopamine and serotonin in rats and their off spring.: 63-70.
- European Commission. (2005). Improving the mental health of the population: Towards a strategy on mental health for the European Union. Health & Consumer Protection. Brussels,: 30.
- Gajdošíková A, Ujházy E, Gajdošík A, Chalupa I, Blaško M, Tomášková A, Liška J, Dubovický M, Bauer V. (1995). Chronic toxicity and micronucleus assay of the new cardioprotective agent stobadine in rats.(5): 531-536.
- Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Decobert M, Françon D, Avenet P, Depoortere H, Tan S, Oblin A, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B. (2001). SL651498: an anxioselective compound with functional selectivity for alpha2- and alpha3-containing gamma-aminobutyric acid(A) (GABA(A)) receptors.(2): 753-768.
- Griebel G, Perrault G, Simiand J, Cohen C, Granger P, Depoortere H, Françon D, Avenet P, Schoemaker H, Evanno Y, Sevrin M, George P, Scatton B. (2003). SL651498, a GABAA Receptor Agonist with Subtype-Selective Efficacy, as a Potential Treatment for Generalized Anxiety Disorder and Muscle Spasms.(1): 3-20.
- Horáková L and Štolc S. (1998). Antioxidant and pharmacodynamic effects of pyridoindole stobadin.(5): 789-799.
- Licata SC, Platt DM, Cook JM, Sarma PV, Griebel G, Rowlett JK. (2005). Contribution of GABAA receptor subtypes to the anxiolytic-like, motor, and discriminative stimulus effects of benzodiazepines: studies with the functionally selective ligand SL651498 [6-fluoro-9-methyl-2-phenyl-4-(pyrrolidin-1-yl-carbonyl)-2,9-dihydro-1-pyridol[3,4-b]indol-1-one].(3): 1118-1125.
- Löw K, Crestani F, Keist R, Benke D, Brünig I, Benson JA, Fritschy JM, Rülicke T, Bluethmann H, Möhler H, Rudolph U. (2000). Molecular and neuronal substrate for the selective attenuation of anxiety.(5489): 131-134.
- Majerčík M, Babinská M, Ujházy E, Babulbvá A, Balónová T. (1984). Six month toxicity of DP 1031 in beagle dogs.:171
- Möhler H and Okada T. (1977). Benzodiazepine receptor: demonstration in the central nervous system.: 849-851.
- Rudolph U, Crestani F, Benke D, Brünig I, Benson JA, Fritschy JM, Martin JR, Bluethmann H, Möhler H. (1999). Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.(6755): 796-800.
- Sandford JJ, Argyropoulos SV, Nutt DJ. (2000). The psychobiology of anxiolytic drugs Part 1: basic neurobiology.(3):197-212.
- Štolc S, Šnirc V, Gajdošíková A, Gajdošík A, Gáspárová Z, Ondrejičková O, Sotníková R, Viola A, Rapta P, Jariabka P, Syneková I, Vajdová M, Zacharová S, Nemček V, Krchnárová V. (2008). New pyridoindoles with antioxidant and neuroprotectve actions,(Bauer V, ed) pp. 118-136, Institute of Experimental Pharmacology Bratislava.
- Wittchen HU and Hoyer J. (2001). Generalized anxiety disorder: nature and course.(11):15-19.
- Wittchen HU and Jacobi F. (2005). Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies.(4): 357-376.
- World Health Organization. (2001).WHO Geneva
Language: English
Page range: 211 - 215
Published on: Feb 6, 2012
Published by: Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
In partnership with: Paradigm Publishing Services
Keywords:
Related subjects:
© 2012 Natália Sedláčková, Veronika Ponechalová, Eduard Ujházy, Michal Dubovický, Mojmír Mach, published by Slovak Academy of Sciences, Institute of Experimental Pharmacology & Toxicology, Centre of Experimental Medicine
This work is licensed under the Creative Commons License.